Uses of Methoflex 500: - Muscle relaxation Muscle Spasm, Tetanus Hypersensitivity, Do not admin parenteral solutions in patients with renal impairment, epilepsy or history of epilepsy. Coma or pre-coma states, brain damage, myasthenia gravis

How to use Methocarbamol: Your doctor or nurse will give you this medicine. Kindly do not self administer. Administration: IV Administration Direct IV: Administer undiluted at not to exceed 3 mL (=300 mg undiluted)/min Infusion: Dilute 1 g with up to 250 mL D5W or NS; avoid extravasation, since injection is hypertonic Administer IV while in recumbent position Maintain position 15-30 min following infusion IM Administration Not to exceed 500 mg (5 mL undiluted) should be given into each gluteal region Adult Dose: Oral Muscle spasm Adult: Initially: 1.5 g q6hr for 48-72 hours; not to exceed 8 g/day THEN decrease to 4-4.5 g/day divided q4-8hr Parenteral 1 g IV/IM; additional doses at q8hr until PO; not to exceed 3 g/day Total parenteral dose should not exceed 3 g/day for >3 days, unless treating tetanus; if condition persists, may repeat therapy after drug-free interval of 48 hr Intravenous Tetanus Adult: Adjunct therapy: Initial 1-2 g IV injection (at 300 mg/min), THEN Additional 1-2 g IV infusion for total dose of 3 g initially May repeat 1-2 g IV q6hr until can give NG or PO Total oral dosage of up to 24 g daily may be needed. Elderly: Dose may need to be reduced by half. Child Dose: Tetanus 15 mg/kg/dose IV q6hr PRN or 500 mg/m²/dose; not to exceed 1.8 g/m²/day for 3 days only Muscle Spasm <16 years: Safety and efficacy not established >16 years: 1500 mg PO q6hr for 48-72 hours; not to exceed 8 g/day THEN decrease to 4-4.5 g/day divided q4-8hr Renal Dose: Renal failure: Not studied; parenteral dosage form contraindicated due to presence of polyethylene glycol

Action potentiated by alcohol and other CNS depressants. May inhibit effect of pyridostigmine, use with caution with anticholinesterase agents.

Hypersensitivity, Do not admin parenteral solutions in patients with renal impairment, epilepsy or history of epilepsy. Coma or pre-coma states, brain damage, myasthenia gravis

Common - Sleepiness - Dryness in mouth Nausea, anorexia, fever, headache, blurred vision, lassitude, drowsiness, dizziness, restlesness, anxiety, confusion, convulsions; hypersensitivity reactions e.g. rashes, pruritus, urticaria, angiodema. Parenteral: Flushing and a metallic taste; incoordination, diplopia, nystagmus, vertigo; sloughing and thrombophloebitis at the site of inj. Potentially Fatal: Parenteral: Syncope, hypotension, bradycardia, anaphylaxis.

Precaution: May cause drowsiness/dizziness; patients should not ingest alcohol or other CNS depressants May take with food to avoid stomach upset Half-life increases with hepatic impairment IV formulation not for use in renal impairment (contains polyethylene glycol; injection rate should not exceed 3 mL/min May interfere with screening tests for 5-HIAA and vanillylmandelic acid (VMA) Use injection with caution in patients with a history of seizures Sedative effects potentiated when used with other sedatives Medication is poorly tolerated in the elderly Pediatric IV dosing approved only for tetanus Lactation: Not known if excreted in breast milk; use caution

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma. In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

Store at controlled room temperature, between 20°C and 25°C

Centrally acting Skeletal Muscle Relaxants

Unknown; Methocarbamol is a centrally acting skeletal muscle relaxant whose precise mode of action is not known. It is said to cause general depression of the central nervous system.

Pregnancy Category C. Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. methocarbamol should be given to a pregnant woman only if clearly needed.Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazardsNursing Mothers: Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol  is administered to a nursing woman.